AMGN•benzinga•
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Summary
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 21, 2025 by benzinga